Exscientia (NASDAQ:EXAI) Stock Price Down 5.3% – Here’s Why

Exscientia plc (NASDAQ:EXAI) traded down 5.3% during mid-day trading on Friday . The company traded as low as $5.01 and last traded at $5.03. 147,384 shares changed hands during trading, a decline of 77% from the average session volume of 640,736 shares. The stock had previously closed at $5.31.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Barclays reissued an “equal weight” rating and set a $5.00 price objective on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen reaffirmed a “hold” rating on shares of Exscientia in a report on Friday, August 9th.

Exscientia Stock Down 9.2 %

The company has a fifty day simple moving average of $5.05 and a 200-day simple moving average of $5.15. The company has a quick ratio of 5.93, a current ratio of 4.54 and a debt-to-equity ratio of 0.06. The firm has a market cap of $612.24 million, a P/E ratio of -3.30 and a beta of 0.83.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). The firm had revenue of $5.60 million for the quarter. Exscientia had a negative return on equity of 49.10% and a negative net margin of 882.09%. On average, equities analysts anticipate that Exscientia plc will post -1.25 earnings per share for the current year.

Institutional Trading of Exscientia

A number of institutional investors and hedge funds have recently bought and sold shares of EXAI. China Universal Asset Management Co. Ltd. increased its position in shares of Exscientia by 66.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock valued at $47,000 after purchasing an additional 3,821 shares during the last quarter. EntryPoint Capital LLC grew its stake in shares of Exscientia by 22.8% during the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock valued at $178,000 after buying an additional 5,784 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Exscientia in the second quarter worth approximately $54,000. International Assets Investment Management LLC bought a new stake in shares of Exscientia during the 3rd quarter worth approximately $77,000. Finally, Federated Hermes Inc. purchased a new position in Exscientia during the 2nd quarter valued at $115,000. 41.58% of the stock is currently owned by institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.